Intriguingly, in the melanoma patients who showed tumor regression after MAGE-A3 vaccination, CTLs against MAGE-C2 were highly present in the blood, with a frequency of 10–10,000 times higher than that of anti-MAGE-A3 CTLs. This evidence concerns the gene MAGEA3 and neoplasm.